FAQ on Clene Inc.'s Q3 2024 Results and ALS Treatment Progress

What were the key highlights from Clene Inc.’s Q3 2024 report?

Key highlights included a discussion with the FDA about accelerated approval for CNM-Au8 for ALS, a 1-for-20 reverse stock split, an amended debt facility extending funding into Q2 2025, and a $7.3 million funding round. The company also presented its Phase 3 RESTORE-ALS trial results.

How did Clene Inc. perform financially in Q3 2024?

Clene ended Q3 with $14.6 million in cash and reported an $8.0 million net loss, which reflected decreased R&D and G&A expenses but lower gains on warrant liability adjustments compared to 2023.

What is CNM-Au8 and what is its significance?

CNM-Au8 is an investigational first-in-class therapy by Clene aimed at improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS, Parkinson’s disease, and multiple sclerosis. It represents a novel approach to treating these conditions by targeting mitochondrial function and the NAD pathway.

What steps has Clene taken to meet Nasdaq requirements?

Clene executed a 1-for-20 reverse stock split as part of its efforts to meet Nasdaq’s minimum bid price requirement.

Where can I find more information about Clene Inc. and its updates?

More information can be found on Clene’s official website at www.Clene.com or in the company’s newsroom at https://ibn.fm/CLNN.

What is the RESTORE-ALS trial?

The RESTORE-ALS trial is Clene’s Phase 3 clinical trial for CNM-Au8, aimed at evaluating its efficacy and safety in treating ALS. It was presented in October, showcasing the company’s commitment to ALS treatment innovation.

How does Clene plan to fund its operations into 2025?

Clene amended its debt facility to extend funding into Q2 2025 and completed a $7.3 million funding round to support its operations and ongoing research.